Celon Pharma S.A. (FRA:8RP)

Celon Pharma Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	20.59	26.85	32.36	82.9	147.8	43.98
Short-Term Investments	-	48.24	82.18	81.72	79.76	-
Cash & Short-Term Investments	20.59	75.09	114.54	164.62	227.55	43.98
Cash Growth	-80.07%	-34.45%	-30.42%	-27.65%	417.42%	-34.06%
Accounts Receivable	47.5	39.26	32.79	27.11	24.67	32.53
Other Receivables	8.04	12.72	15.45	6.59	2.57	9.49
Receivables	55.55	51.99	48.24	33.7	27.25	42.02
Inventory	23.1	30.17	26.41	38.39	23.38	29.76
Other Current Assets	3.94	3.18	0.56	0.87	0.53	3.48
Total Current Assets	103.17	160.43	189.75	237.58	278.7	119.24
Property, Plant & Equipment	294.66	311.66	333.8	341.59	316.57	313.8
Long-Term Investments	15.83	32.56	11.26	13.25	38.12	12.87
Other Intangible Assets	2.71	8.15	14.29	21.15	27.81	38.38
Long-Term Deferred Tax Assets	18.46	21.55	19.05	28.14	31.94	27.17
Long-Term Deferred Charges	-	-	0.68	0.68	1.36	2.72
Other Long-Term Assets	36.51	9.46	0.47	0.38	12.64	17.7
Total Assets	471.34	543.8	569.31	642.76	707.14	531.89
Accounts Payable	10.86	15.43	10.51	17.47	11.87	18.42
Accrued Expenses	9.61	8.1	7.39	6.8	3.11	6.77
Short-Term Debt	0.53	1.53	12.75	-	-	12.84
Current Portion of Leases	7.2	7.14	7.13	19.43	6.56	3.49
Current Unearned Revenue	11.67	17.92	31.09	56.42	55.83	45.78
Other Current Liabilities	14.5	16.78	17.48	16.32	8.99	26.86
Total Current Liabilities	54.38	66.9	86.34	116.44	86.36	114.15
Long-Term Leases	6.46	8.26	5.71	7.39	8.35	9.16
Long-Term Unearned Revenue	20.37	20.22	22.88	25.62	29.85	39.67
Long-Term Deferred Tax Liabilities	0.31	2.85	3.01	1.32	6.04	-
Other Long-Term Liabilities	0.62	0.36	5.81	12.35	22.53	24.38
Total Liabilities	82.14	98.59	123.75	163.12	153.14	187.36
Common Stock	5.39	5.39	5.11	5.1	5.1	4.5
Additional Paid-In Capital	516.81	551.25	543.23	587.1	613.51	393.12
Retained Earnings	-135.01	-114.96	-108.64	-119.79	-91.67	-58.57
Comprehensive Income & Other	2.01	3.53	5.85	7.23	27.07	5.48
Shareholders' Equity	389.19	445.21	445.56	479.65	554	344.53
Total Liabilities & Equity	471.34	543.8	569.31	642.76	707.14	531.89
Total Debt	14.19	16.93	25.59	26.82	14.92	25.48
Net Cash (Debt)	6.4	58.16	88.95	137.8	212.63	18.5
Net Cash Growth	-92.81%	-34.62%	-35.45%	-35.19%	1049.56%	-71.56%
Net Cash Per Share	0.12	1.11	1.74	2.70	4.55	0.41
Filing Date Shares Outstanding	52.33	53.86	51.06	51.04	51	45
Total Common Shares Outstanding	52.33	53.86	51.06	51.04	51	45
Working Capital	48.79	93.53	103.41	121.14	192.34	5.1
Book Value Per Share	7.44	8.27	8.73	9.40	10.86	7.66
Tangible Book Value	386.48	437.06	431.26	458.5	526.19	306.16
Tangible Book Value Per Share	7.39	8.12	8.45	8.98	10.32	6.80
Land	-	6.35	6.35	6.35	6.35	6.35
Buildings	-	157.97	146.4	146.35	146.08	173.5
Machinery	-	317.71	272.86	190.43	177.34	164.34
Construction In Progress	-	15.75	79.95	74.3	50.63	31.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.